The three goals of the Cancer Therapeutic Program are: 1) to enhance and facilitate programmatic and interprogrammatic interaction and collaboration between basic scientists and clinical investigators in cancer therapeutics;2) to promote the discovery, development, and application of novel therapeutic approaches;and 3) to develop translational and laboratory-based clinical investigations of new therapeutic agents and new therapeutic approaches. These goals are achieved through three Research Themes. Theme 1 is focused on technology development for target identification and drug discovery, with the goal of applying these new technologies (such as combinatorial chemistry, medicinal chemistry, computational biology, structural biology, nanotechnology, and high-throughput assays) to specific drug development projects in theme 2. For example, in theme 2, we are developing: cancer cell surface targeting ligands, novel targeting nanocarriers for cancer drug delivery and imaging, tyrosine kinase inhibitors, and nanoparticles for cancer vaccine and immunotherapy. In Theme 3, we use a collaborative group of molecular biologists, translational scientists, pharmacologists, and clinical investigators to facilitate the design and conduct of laboratory-driven clinical investigations. In view of the preclinical expertise in drug discovery and drug development available within the Program, there is great potential to translate promising new therapeutic leads into clinical trials and associated laboratory correlative studies. One example of such translation is the development of novel nanoformulations of paclitaxel soon to be tested in human. Furthermore, the expertise represented within this group of investigators provides a conduit for acquisition of new therapeutic agents from the NCI or industry. Providing a platform for clinical trials are specific project areas in clinical investigation and translational studies, including drug development awards (N01, U01, U10) and investigator-initiated trials. The program has 46 members from 13 different departments at UC Davis and 1 department at LLNL. It has 25 NCl-funded projects for $3.9 million ADC (total peer-reviewed funding, $8.8 million ADC). Of the 728 publications for the last funding period, 44% are inter-programmatic and 29% are intra-programmatic.

Public Health Relevance

Through the three interactive research themes, investigators from the Cancer Therapeutic Program will translate promising new therapeutic leads into clinical trials and associated laboratory correlative studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-12
Application #
8743641
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
12
Fiscal Year
2014
Total Cost
$22,224
Indirect Cost
$7,745
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Semrad, Thomas; Barzi, Afsaneh; Lenz, Heinz-Josef et al. (2015) Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol 20:518-24
Brostoff, Terza; Dela Cruz Jr, Florante N; Church, Molly E et al. (2014) The raccoon polyomavirus genome and tumor antigen transcription are stable and abundant in neuroglial tumors. J Virol 88:12816-24
Kirschbaum, Mark H; Foon, Kenneth A; Frankel, Paul et al. (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55:2301-4
Mayadev, Jyoti; Qi, Lihong; Lentz, Susan et al. (2014) Implant time and process efficiency for CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy 13:233-9
Daly, Megan E; Beckett, Laurel A; Chen, Allen M (2014) Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? Pract Radiat Oncol 4:240-6
Li, Tianhong; Maus, Martin K H; Desai, Sonal J et al. (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 9:18-25
Campbell, Mel; Kim, Kevin Y; Chang, Pei-Ching et al. (2014) A lytic viral long noncoding RNA modulates the function of a latent protein. J Virol 88:1843-8
Li, Tianhong; Kung, Hsing-Jien; Mack, Philip C et al. (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31:1039-49
Semrad, Thomas J; Eddings, Courtney; Dutia, Mrinal P et al. (2013) Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs 24:636-40
Maus, Martin K H; Mack, Philip C; Astrow, Stephanie H et al. (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8:582-6

Showing the most recent 10 out of 84 publications